Leukemia/Lymphoma

Adult T Cell Leukemia/Lymphoma:

IRB #H-37452/ LCCC #1637: Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group

Chronic Lymphocytic Leukemia/Small Cell Lymphoma:

IRB #H-39342 / DFCI #18-089: A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Patients with Richter’s Syndrome (not yet submitted to IRB)

Hodgkin Lymphoma:

CIRB #pend/ SWOG #S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (not yet submitted to IRB)